Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD. Moreno L, et al. Among authors: chesler l. Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Expert Opin Drug Discov. 2017. PMID: 28604107 Free article. Review.
Preclinical drug development for childhood cancer.
Moreno L, Chesler L, Hargrave D, Eccles SA, Pearson AD. Moreno L, et al. Among authors: chesler l. Expert Opin Drug Discov. 2011 Jan;6(1):49-64. doi: 10.1517/17460441.2011.537652. Epub 2010 Nov 24. Expert Opin Drug Discov. 2011. PMID: 22646826
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE. Berry T, et al. Among authors: chesler l. Cancer Cell. 2012 Jul 10;22(1):117-30. doi: 10.1016/j.ccr.2012.06.001. Cancer Cell. 2012. PMID: 22789543 Free PMC article.
Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.
Jamin Y, Tucker ER, Poon E, Popov S, Vaughan L, Boult JK, Webber H, Hallsworth A, Baker LC, Jones C, Koh DM, Pearson AD, Chesler L, Robinson SP. Jamin Y, et al. Among authors: chesler l. Radiology. 2013 Jan;266(1):130-40. doi: 10.1148/radiol.12120128. Epub 2012 Nov 20. Radiology. 2013. PMID: 23169794 Free PMC article.
New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.
Barone G, Anderson J, Pearson AD, Petrie K, Chesler L. Barone G, et al. Among authors: chesler l. Clin Cancer Res. 2013 Nov 1;19(21):5814-21. doi: 10.1158/1078-0432.CCR-13-0680. Epub 2013 Aug 21. Clin Cancer Res. 2013. PMID: 23965898 Free PMC article. Review.
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME, Poon E, Ebus ME, den Hartog IJ, van Noesel CJ, Jamin Y, Hallsworth A, Robinson SP, Petrie K, Sparidans RW, Kok RJ, Versteeg R, Caron HN, Chesler L, Molenaar JJ. Dolman ME, et al. Among authors: chesler l. Clin Cancer Res. 2015 Nov 15;21(22):5100-9. doi: 10.1158/1078-0432.CCR-15-0313. Epub 2015 Jul 22. Clin Cancer Res. 2015. PMID: 26202950 Free PMC article.
111 results